Talis Biomedical

Talis Biomedical P/B

Delisted

The P/B (Price-to-Book Ratio) of Talis Biomedical (TLIS) as of Oct 17, 2026 is 0.07. In the previous year, P/B (Price-to-Book Ratio) was 0.04 — a change of 83.37% (higher).

P/B

0.07

YoY

83.37%

Last updated:

P/B (Price-to-Book Ratio) of Talis Biomedical is 2023 0.07 . P/B (Price-to-Book Ratio) of Talis Biomedical was 2022 0.04 . It decreases by 83.37% higher compared to the previous year.

The Talis Biomedical P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
0.67 USD
Jan 1, 2019
0.24 USD
Jan 1, 2020
0.03 USD
Jan 1, 2021
0.02 USD
Jan 1, 2022
0.04 USD
Jan 1, 2023
0.07 USD
The Talis Biomedical P/B history
YEARP/BYoY
0.07+83.37%
0.04+84.61%
0.02-22.05%
0.03-88.15%
0.24-64.40%
0.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Talis Biomedical Stock analysis

What does Talis Biomedical do? Talis Biomedical Corp, headquartered in Redwood City, California, operates in the Health Care Equipment & Supplies sector. The company, listed on 12 February 2021, employs 102 full-time staff. It develops and commercializes point-of-care molecular diagnostic products, focusing on the Talis One system—a cloud-enabled platform combining a compact instrument, single-use cartridges, and software for central laboratory accuracy. The firm targets infectious disease testing, including respiratory infections, women's health, and STIs, with assays for influenza A/B and a respiratory panel integrating COVID-19 testing. Talis Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talis Biomedical stock

P/B (Price-to-Book Ratio) of Talis Biomedical is 0.07 in 2023.

P/B (Price-to-Book Ratio) of Talis Biomedical changed from 0.04 to 0.07, representing a 83.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Talis Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Talis Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Talis Biomedical

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Talis Biomedical